



International Journal of Biology Sciences

ISSN Print: 2664-9926
 ISSN Online: 2664-9934
 NAAS Rating (2025): 4.82
 IJBS 2025; 7(11): 40-42
www.biologyjournal.net
 Received: 19-08-2025
 Accepted: 22-09-2025

Sanjay HV
 MVSc scholar, Department of
 Veterinary Medicine,
 Veterinary College, Bengaluru,
 Karnataka, India

Chetan Kumar GK
 Assistant Professor,
 Department of Veterinary
 Medicine, Veterinary College,
 Bengaluru, Karnataka, India

D Rathnamma
 Director, Institute of Animal
 Health and Veterinary
 Biologicals, Bengaluru,
 Karnataka, India

Corresponding Author:
Sanjay HV
 MVSc scholar, Department of
 Veterinary Medicine,
 Veterinary College, Bengaluru,
 Karnataka, India

Comparative evaluation of lateral flow assay and polymerase chain reaction in the detection of canine parvovirus

Sanjay HV, Chetan Kumar GK and D Rathnamma

DOI: <https://www.doi.org/10.33545/26649926.2025.v7.i11a.516>

Abstract

Canine parvovirus (CPV) infection poses a significant threat to the health and well-being of dogs worldwide. It is a small, non-enveloped virus consisting of linear, single-stranded negative-sense DNA of approximately 5 kb in length. The present study was conducted in Department of Veterinary Medicine, Veterinary College, Bengaluru to assess the efficacy of lateral flow assay (LFA) in comparison to the conventional polymerase chain reaction (PCR) in detecting CPV antigen in the faecal samples of CPV- suspected dogs under one year of age. CPV antigen was detected by LFA in 44 percent of the suspected dogs, whereas PCR detected CPV DNA in 72 percent. PCR targeting partial VP (Viral Protein)-2 gene, yielding the amplicon size of 630 base pairs (bp) was performed. The specificity and sensitivity of LFA was 100 and 61.1 percent, respectively, in comparison with the PCR. Although LFA allow patient side diagnosis PCR remains the most sensitive and reliable method for the confirmatory detection of CPV infection in clinical cases.

Keywords: Canine parvovirus, polymerase chain reaction, lateral flow assay, sensitivity

Introduction

Canine parvovirus (CPV) 2 is a major canine pathogen that causes hemorrhagic gastroenteritis and can also induce myocarditis in dogs. Identified in 1977, it has become a global enteric virus in canines, with high morbidity and mortality reported up to about 10 percent with treatment and 90 percent without treatment (Olaifa *et al.*, 2025) ^[10]. Several diagnostic methods exist in research settings for CPV detection, including hemagglutination assays, immunofluorescence, enzyme linked immunosorbent assay (ELISA), polymerase chain reaction (PCR), lateral flow assay (LFA) and cell culture, but in routine veterinary hospital laboratories, the most commonly used techniques are the LFA and PCR (Faz *et al.*, 2017) ^[4]. The positive LFA results were considered reliable, but negative results required PCR confirmation, reinforcing that clinical diagnosis alone was indecisive and that laboratory confirmation on faeces was essential with PCR (Khajeh-Kazerooni, 2020) ^[7]. The present compared the sensitivity and specificity of LFA and PCR.

Materials And Methods

The study population comprised of 50 dogs below one year of age, that were presented to the Department of Veterinary Medicine, Veterinary College, Bengaluru, exhibiting clinical manifestations suggestive of CPV infection, including anorexia, vomiting, diarrhoea and lethargy. All the faecal samples of the study population underwent LFA and PCR for the confirmation of CPV antigen.

The manufacturer's guidelines were followed LFA, using LFA kits (Canine Parvo Virus Ag Rapid Test, PetX, J&G Biotech Ltd., London, England). Faecal samples were collected from dog's rectum using a sterile cotton swab and were added into the provided assay buffer tube and agitated. The test device was taken out from the package just prior to examination and placed it horizontally on the table and about two millilitres of assay buffer containing the sample was sucked into a dropper provided, and five drops of it was placed into the sample hole "S" of the test device. The result was interpreted within five to 10 minutes. Only clear control (C) line, with no test (T) line was reported as negative, whereas presence of both C

line and T line was reported as positive. If no coloured line appeared in C zone, irrespective of T line, the test was declared invalid. The faecal samples were stored at -20°C for further analysis.

The extraction of viral DNA from faecal samples was conducted in accordance with the manufacturer's instructions using DNA extraction kit (DNeasy, QIAGEN, Germany). In a 1.5 mL microcentrifuge tube, 200 µL of the sample was mixed with 200 µL of the lysis buffer (Buffer ATL) and 20 µL of Proteinase K. The mixture was thoroughly vortexed to ensure complete lysis. Subsequently, 200 µL of absolute ethanol was added, and the solution was mixed again by vortexing. The entire lysate, including any precipitate, was then transferred to a DNeasy Mini spin column placed in a two mL collection tube and centrifuged at 8000 rpm for one minute. The flow-through and collection tube were discarded. The column was transferred to a new collection tube and 500 µL of Buffer AW1 was added before centrifugation at 8000 rpm for one minute. The flow-through and tube were again discarded and 500 µL of Buffer AW2 was added to the column, followed by centrifugation at 14,000 rpm for three minutes. Finally, the column was placed in a clean 1.5 mL microcentrifuge tube and 200 µL of Buffer AE was added directly to the membrane. After incubation at room temperature for one minute, DNA was eluted by centrifugation at 8000 rpm for one minute. The DNA from a known CPV-positive sample was extracted and used as the positive control. Nuclease free water was used as no template control (NTC). The quantity and purity of the extracted DNA was evaluated, before preparing the PCR reaction mix, using nucleic acid analyser (Genetix, Biotech Asia, India). The extracted DNA was stored at -80 °C till further analysis. Conventional PCR targeting the partial viral protein (VP)-2 capsid protein gene yielding amplicon size of 630 base pairs (bp) was performed as described by Buonavoglia *et al.* (2001), using the forward primer (CAGGTGATGAATTTGCTACA) and reverse primer (CATTTGGATAAACTGGTGGT) for the positions 3556–3575 and 4166–4185, respectively. The PCR was carried out in a final reaction volume of 25 µL. Each reaction mixture consisted of 12.5 µL of 2X PCR Master Mix, 5.5 µL of nuclease-free water, five µL of template DNA, one µL each of forward and reverse primers. The PCR amplification

was performed under the following thermal cycling conditions, an initial denaturation at 95 °C for five minutes, followed by 35 cycles consisting of denaturation at 95 °C for 30 seconds, annealing at 56 °C for 30 seconds, and extension at 72 °C for one minute. This was followed by a final extension step at 72 °C for 10 minutes, and the reaction was then held at 4 °C until further analysis.

Ten microliters of the PCR products were loaded into their respective wells in the 1.5 percent agarose gel, along with 10 microlitre 100 base pair ladder in a single separate well. Electrophoresis device was done at 50 Volts capacity for 45 minutes and gel was analysed in a UV transilluminator for visualization of bands. The results were documented by using a gel documentation system (GELSTAN 1312, Medicare Scientific Supplies, India).



Fig 1: Picture showing negative result for CPV in LFA

3. Results and Discussion

Of the 50 samples analysed using LFA, 44 percent (22) tested positive (Fig. 2) for CPV antigen, while 56 percent (28) tested negative (Fig. 1). PCR (Fig. 3) detected CPV antigen in 72 percent (36) samples, whereas 28 percent (14) samples were negative. Compared to PCR, LFA had 100 percent specificity and 61.1 percent sensitivity.



Fig 2: Picture showing positive result for CPV in LFA



Fig 3: Picture showing gel documentation of PCR products of amplicon size 630bp from five CPV-suspected faecal samples (S1-S5), with DNA ladder (M), positive control (+) and negative control (-)

In the late 1970s, CPV-2 appeared as a novel virus, but CPV-2a, CPV-2b and CPV-2c variant replaced the original virus type completely within a few years. The changes in the host range, ability to replicate in cats and other tissue culture

cells were attributed to the genetic and antigenic changes in the variants (Miranda and Thompson, 2016) [18]. CPV-2 was shed in the vomitus or faeces of infected animals, which led

to the infection in naive or poorly immunized dogs through oronasal exposure (Ford *et al.* 2017) ^[5].

Although LFA allow patient side diagnosis, likelihood of false negatives in LFA has been attributed to low faecal viral loads during early infection or the neutralization of antigen by antibodies in the intestinal lumen (Navarro, 2020; Tangolli *et al.*, 2024) ^[9, 13]. Sensitivity of LFA was improved substantially when tests were performed immediately after collection, thus negative LFA results did not exclude CPV, particularly with recent vaccination or stored samples (Kantere *et al.* 2015) ^[9]. Dogs tested too early in the course of infection might not yet shed detectable levels of virus, contributing to false-negative LFA outcomes, but clinical signs, including severity and prognosis, did not significantly differ between LFA-positive and LFA-negative dogs, except for a variation in defecation frequency (Proksch *et al.* 2015) ^[11].

The most sensitive and reliable method for the confirmatory detection of CPV infection in clinical cases was PCR, as demonstrated in the present study (Navarro, 2020; Tangolli *et al.*, 2024) ^[9, 13]. PCR detects lower viral loads, improving case detection when viral shedding is low or intermittent and can identify CPV DNA before peak fecal shedding, enabling earlier isolation and treatment decisions (Decaro *et al.*, 2005; Desario *et al.*, 2005) ^[2, 3]. False negatives can occur with PCR due to inhibitors in feces, suboptimal sampling or late-stage disease and conversely, PCR may detect residual or non-replicating DNA, necessitating clinical correlation (Wang *et al.*, 2016) ^[14]. PCR can also be used for detection of viral DNA from various tissues like heart and bone marrow, which is helpful in understanding the pathogenesis of the disease (Stancu *et al.*, 2025) ^[12].

Conclusion

Though LFA enables point-of-care diagnosis, the higher percentage of false negatives has been linked to reduced fecal viral shedding in the early stages of infection or antigen neutralization by antibodies. In contrast, PCR continues to be the most sensitive and specific technique for confirming CPV infection in clinical cases, as shown in the present study.

References

1. Buonavoglia C, Martella V, Pratelli A, Tempesta M, Cavalli A, Buonavoglia D, *et al.* Evidence for evolution of canine parvovirus type 2 in Italy. *J Gen Virol.* 2001 Dec;82(12):3021-3025.
2. Decaro N, Elia G, Martella V, Campolo M, Desario C, Camero M, *et al.* A real-time PCR assay for rapid detection and quantitation of canine parvovirus type 2 DNA in the feces of dogs. *Vet Microbiol.* 2005 Jan;105(1):19-28.
3. Desario C, Decaro N, Campolo M, Cavalli A, Cirone F, Elia G, *et al.* Canine parvovirus infection: which diagnostic test for virus? *J Virol Methods.* 2005 Sep;126(1):179-185.
4. Faz M, Rojas M, Segura-Correa JC, Cob-Galera L, Echeverría JC, Larios HM. Reliability of clinical diagnosis and laboratory testing for canine parvovirus type 2 in Mexico. *PLoS One.* 2017 Nov;12(11):18-24.
5. Ford J, McEndaffer L, Renshaw R, Molesan A, Kelly K. Parvovirus infection is associated with myocarditis and myocardial fibrosis in young dogs. *Vet Pathol.* 2017 Nov;54(6):964-971.
6. Kantere M, Athanasiou LV, Chatzopoulos D, Martellos P, Kanellos T, Ikononopoulos J, Polizopoulou Z. Evaluation of a rapid in-clinic test for the detection of canine parvovirus. *J Small Anim Pract.* 2015 Jun;56(6):389-393.
7. Khajeh-Kazerooni S. Canine parvovirus infection: clinical features and diagnostic approaches. *Vet Res Forum.* 2020 Sep;11(3):241-248.
8. Miranda C, Thompson G. Canine parvovirus: the worldwide occurrence of antigenic variants. *J Gen Virol.* 2016 Sep;97(9):2043-2057.
9. Navarro C. Diagnosis of canine parvovirus infection: updates and pitfalls. *Top Companion Anim Med.* 2020 Jun;39:100-108.
10. Olaifa S, Ajayi O, Akande F, Adebisi A, Ahmed S. Clinical outcome of canine parvoviral enteritis: a systematic review and meta-analysis. *Front Vet Sci.* 2025 Feb;12:15-21.
11. Proksch AL, Unterer S, Speck S, Truyen U, Hartmann K, Straubinger RK. Influence of clinical and laboratory variables on fecal antigen ELISA results in dogs with canine parvovirus infection. *Vet J.* 2015 Dec;204(3):304-308.
12. Stancu A, Cârșina D, Bîrzan C, Gherghel I, Tănase A. Detection of canine parvovirus DNA in cardiac and hematopoietic tissues of infected dogs using PCR. *Animals.* 2025 Mar;15(3):512-521.
13. Tangolli G, Patil S, Kumar A, Reddy P, Joseph J. Performance of rapid antigen tests versus PCR for canine parvovirus diagnosis in clinical practice. *Vet Sci.* 2024 Feb;11(2):87-94.
14. Wang J, Liu L, Li R, Li J, Yang J, Xie Q, *et al.* Rapid and sensitive detection of canine parvovirus type 2 by recombinase polymerase amplification. *Sci Rep.* 2016 Feb;6:25-33.